title: Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial.
abstract: We carried out a double blind multicentre clinical trial in which 171 patients with advanced breast cancer were randomized to receive tamoxifen (30 mg/day) + bromocriptine (5 mg/day) or tamoxifen + placebo. No difference was found in the overall response rates in the two groups (37.5% for placebo; 38% for bromocriptine) or in subgroups (breast tumours, lymph nodes, lung, bone, skin metastases). Tolerability was good in both groups. Within the limits of the statistical power of the test (80%), our results do not show any benefit when bromocriptine was added to tamoxifen.
authors.affiliation: Centre Oscar Lambret, Lille, France.
authors.forename: J
authors.initials: J
authors.lastname: Bonneterre
authors.forename: L
authors.initials: L
authors.lastname: Mauriac
authors.forename: B
authors.initials: B
authors.lastname: Weber
authors.forename: H
authors.initials: H
authors.lastname: Roche
authors.forename: P
authors.initials: P
authors.lastname: Fargeot
authors.forename: M
authors.initials: M
authors.lastname: Tubiana-Hulin
authors.forename: M
authors.initials: M
authors.lastname: Sevin
authors.forename: P
authors.initials: P
authors.lastname: Chollet
authors.forename: P
authors.initials: P
authors.lastname: Cappelaere
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D001971:Bromocriptine / Q000008:administration & dosage; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015337:Multicenter Studies as Topic; D013629:Tamoxifen / Q000008:administration & dosage
chemical_list: D013629:Tamoxifen; D001971:Bromocriptine